Inventor · disambiguated record
Pan Zheng
Also filed as: ZHENG PAN
29 granted patents·32 pending applications·67 citations·filing 2001–2025
95Inventor score
Top patents by PatentIndex Score
61 records- 0195US10618960B2Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereofONCOIMMUNE INC·Filed 2016·Granted Apr 14, 2020·12 cites·14 claims
- 0293US12227557B2CD80 and CD86 binding protein compositions and uses thereofONCOC4 INC·Filed 2022·Granted Feb 18, 2025·2 cites·20 claims
- 0386US11261233B2CD80 and CD86 binding protein compositions and uses thereofONCOC4 INC·Filed 2017·Granted Mar 1, 2022·6 cites·19 claims
- 0485US10369197B2Use of CD24 for lowering low-density lipoprotein cholesterol levelsONCOLMMUNE INC·Filed 2016·Granted Aug 6, 2019·3 cites·21 claims
- 0582US10793617B2Methods of use of soluble CD24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2018·Granted Oct 6, 2020·1 cites·14 claims
- 0682US9611309B2Methods of use of soluble CD24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2014·Granted Apr 4, 2017·2 cites·17 claims
- 0781US8895022B2Methods of use of soluble CD24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2013·Granted Nov 25, 2014·2 cites·9 claims
- 0881US8163281B2Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axisLIU YANG·Filed 2010·Granted Apr 24, 2012·4 cites·3 claims
- 0981US7744894B2Method of treating multiple sclerosis and related t-cell initiated tissue destruction by administering HSA/CD24LIU YANG·Filed 2005·Granted Jun 29, 2010·4 cites·6 claims
- 1081US7504554B2Animal model for identifying agents that inhibit or enhance CTLA4 signalingUNIV OHIO STATE RES FOUND·Filed 2007·Granted Mar 17, 2009·9 cites·4 claims
- 1180US11026995B2Use of CD24 for lowering low-density lipoprotein cholesterol levelsONCOLMMUNE INC·Filed 2019·Granted Jun 8, 2021·1 cites·16 claims
- 1279US12473362B2Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereofONCOC4 INC·Filed 2023·Granted Nov 18, 2025·0 cites·12 claims
- 1377US8808697B2Methods of use of soluble CD24 for therapy of rheumatoid arthritisZHENG XINCHENG·Filed 2011·Granted Aug 19, 2014·6 cites·6 claims
- 1476US12441780B2CD80 and CD86 binding protein compositions and uses thereofONCOC4 INC·Filed 2022·Granted Oct 14, 2025·0 cites·17 claims
- 1575US7161058B2Animal model for identifying agents that inhibit or enhance CTLA4 signalingUNIV OHIO STATE RES FOUND·Filed 2005·Granted Jan 9, 2007·5 cites·4 claims
- 1674US2025043003A1Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effectsONCOC4 INC·Filed 2024·Application pending·0 cites
- 1772US2020399345A1Methods of use of soluble cd24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2020·Application pending·0 cites
- 1871US2021161991A1Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2020·Application pending·0 cites
- 1970US8158596B2Materials and methods for FOXP3 tumor suppressionLIU YANG·Filed 2008·Granted Apr 17, 2012·2 cites·9 claims
- 2069US2020147167A1Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2020·Application pending·0 cites
- 2167US11629188B2Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereofONCOC4 INC·Filed 2020·Granted Apr 18, 2023·0 cites·12 claims
- 2267US6875904B2Animal model for identifying agents that inhibit or enhance CTLA4 signalingUNIV OHIO STATE RES FOUND·Filed 2001·Granted Apr 5, 2005·8 cites·3 claims
- 2365US2019255140A1Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2019·Application pending·0 cites
- 2463US12129299B2Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effectsONCOC4 INC·Filed 2019·Granted Oct 29, 2024·0 cites·6 claims
- 2563US9877998B2Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2017·Granted Jan 30, 2018·0 cites·6 claims
- 2663US2025333532A1Glycan-shielded cd24 epitopes and uses thereofONCOC4 INC·Filed 2025·Application pending·0 cites
- 2763US2025243292A1Anti-cd24 compositions and uses thereofONCOC4 INC·Filed 2025·Application pending·0 cites
- 2863US2022098278A1Methods of Use of Soluble CD24 for Neuroprotection and RemyelinationONCOLMMUNE INC·Filed 2021·Application pending·0 cites
- 2962US2018177841A1Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2017·Application pending·0 cites
- 3062US2017233453A1Methods of use of soluble cd24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2017·Application pending·0 cites
- 3162US2013231464A1Methods of use of soluble cd24 for therapy of rheumatoid arthritisONCOLMMUNE INC·Filed 2013·Application pending·0 cites
- 3261US2013296249A1Methods of blocking tissue destruction by autoreactive t cellsLIU YANG·Filed 2013·Application pending·0 cites
- 3360US9623070B2Uses of hypoxia-inducible factor inhibitorsONCOLMMUNE INC·Filed 2016·Granted Apr 18, 2017·0 cites·6 claims
- 3459US11571461B2Methods of use of soluble CD24 for treating lupus nephritisONCOIMMUNE INC·Filed 2018·Granted Feb 7, 2023·0 cites·11 claims
- 3559US8637013B2Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axisLIU YANG·Filed 2012·Granted Jan 28, 2014·0 cites·8 claims
- 3659US2012294884A1Methods of blocking tissue destruction by autoreactive t cellsLIU YANG·Filed 2012·Application pending·0 cites
- 3758US12286485B2Anti-CD24 compositions and uses thereofONCOC4 INC·Filed 2019·Granted Apr 29, 2025·0 cites·13 claims
- 3858US2024139280A1Use of hif-1-alpha inhibitors in cancer immunotherapyONCOC4 INC·Filed 2022·Application pending·0 cites
- 3958US2021162006A1Use of CD24 Proteins for Treating Leptin-Deficient ConditionsONCOIMMUNE INC·Filed 2020·Application pending·0 cites
- 4058US2024218067A1Anti-siglec compositions and uses thereofONCOC4 INC·Filed 2022·Application pending·0 cites
- 4157US10799558B2Use of CD24 proteins for treating leptin-deficient conditionsONCOIMMUNE INC·Filed 2017·Granted Oct 13, 2020·0 cites·19 claims
- 4257US2025257117A1Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancerONCOC4 INC·Filed 2023·Application pending·0 cites
- 4356US9427413B2Uses of hypoxia-inducible factor inhibitorsLIU YANG·Filed 2010·Granted Aug 30, 2016·0 cites·3 claims
- 4454US11911441B2Methods of use of CD24 for the prevention and treatment of leukemia relapseONCOIMMUNE INC·Filed 2019·Granted Feb 27, 2024·0 cites·16 claims
- 4552US2023108492A1Methods of use of soluble cd24 for treating viral pneumoniaONCOIMMUNE INC·Filed 2021·Application pending·0 cites
- 4651US2003106084A1Methods of blocking tissue destruction by autoreactive T cellsFiled 2002·Application pending·0 cites
- 4751US2024156373A1Real-Time Blood Glucose Monitoring Apparatus and Manufacturing Method ThereforMICROTECH MEDICAL HANGZHOU CO LTD·Filed 2022·Application pending·0 cites
- 4850US2020181235A1Methods of use of soluble cd24 for neuroprotection and remyelinationONCOIMMUNE INC·Filed 2018·Application pending·0 cites
- 4949US2005214290A1Methods of blocking tissue destruction by autoreactive T cellsLIU YANG·Filed 2005·Application pending·0 cites
- 5048US2023103352A1Methods of use of soluble cd24 for treating sars-cov-2 infectionONCOIMMUNE INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Pan Zheng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →